Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00043342
Status:
COMPLETED
Last Update Posted:
2007-11-01
First Post:
2002-08-07
Brief Title:
Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis
Sponsor:
InterMune
Organization:
InterMune
Study Overview
Official Title:
A Phase III Study of Interferon Gamma-1b by Subcutaneous Injection for the Treatment of Patients With Cystic Fibrosis
Status:
COMPLETED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to evaluate the safety tolerability and efficacy of Interferon gamma-1b IFN-gamma 1b when administered by subcutaneous injection over a period of 4 weeks to patients with mild-to-moderate cystic fibrosis Additionally preliminary assessments on the effects of IFN-gamma 1b on lung function and other indicators of health will be made
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None